Scytonemin

Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent inhibition (IC50=2.0 μM) of polo-like kinase 1 (PLK1) -mediated cdc25C phosphorylation, and plays an important role in regulating the G2/M transition in the cell cycle. It can be used in the research of cancer, acute inflammation and sunscreen cosmetics[1][2][3][4][5].

Product Specifications

CAS Number

[152075-98-4]

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Apoptosis; Polo-like Kinase (PLK) ; Reactive Oxygen Species (ROS)

Type

Natural Products

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/scytonemin.html

Purity

99.53

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(/C1=C\C2=CC=C(O)C=C2)C(C(C(/C3=C\C4=CC=C(O)C=C4)=O)=C5C3=NC6=C5C=CC=C6)=C7C1=NC8=C7C=CC=C8

Molecular Formula

C36H20N2O4

Molecular Weight

544.56

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Proteau PJ, et al. The structure of scytonemin, an ultraviolet sunscreen pigment from the sheaths of cyanobacteria. Experientia. 1993 Sep 15;49 (9) :825-9.|[2]Rastogi RP, et al. Cyanobacterial Sunscreen Scytonemin: Role in Photoprotection and Biomedical Research. Appl Biochem Biotechnol. 2015 Jul;176 (6) :1551-63.|[3]Gerwick, et al. "Antimutagenic, antiinflammatory, and potential anticancer substances from marine algae." Food Factors for Cancer Prevention. Springer Japan, 1997.|[4]Stevenson, et al. "The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore." Journal of Pharmacology and Experimental Therapeutics 303.2 (2002) : 858-866.|[5]Degenhardt, et al. "Targeting Polo-like kinase in cancer therapy." Clinical cancer research 16.2 (2010) : 384-389.